Biotech firm Odyssey targets $810 million in valuation in US IPO

May 4 (Reuters) - Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States.

The company is seeking to raise up to $238.3 million by offering 13.2 million shares priced between $16 and $18 apiece.

The U.S. IPO market is showing early signs of reopening, with April marking the busiest month for new filings in over four years and setting the stage for a potential pickup in listings in the coming months, according to Renaissance Capital, a provider of IPO-focused research and ETFs.

Odyssey Therapeutics intends to list on the Nasdaq Capital Market under the symbol "ODTX".

J.P. Morgan, TD Cowen and Cantor are among the underwriters for the offering.